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Introduction
Antineutrophil cytoplasmic antibody (ANCA) associated
vasculitides involve pauci-immune small vessel vasculitis that
can lead to rapidly progressive glomerulonephritis. This case
series examines the role of ANCA titers such as proteinase 3
(PR3) and myeloperoxidase (MPO) antibodies in assessing
disease activity.

Biomarkers:
ANCA
CRP
Platelets

Clinical disease:
Signs and symptoms

Subclinical disease:
No signs and symptoms
Persistent inflammation
and failure of resolution
Precursors of relapse ?

T-cell subsets
Calprotectin
Urinary: sCD163,
Lymphocytes,
and sCD25

Clinically overt disease versus subclinical persistent inflammation in ANCAassociated vasculitis. Figure adapted from Salama (2020).

Case Presentations
Case 1 involves a 63 year old female with microscopic
polyangitis who developed pulmonary-renal syndrome
requiring intubation, plasmapheresis and immunosuppression.
Table 1 shows anti-MPO titer elevated to 80 U/ml with
proteinuria and acute kidney injury.

Table 1. Case Series of ANCA vasculitis associated glomerulonephritis
Case #, sex, age,
Renal function
Renal function
Special labs
Treatment course
diagnosis
at remission
at relapse
Case 1:
Creatinine
Creatinine
• P-ANCA titer 1:80
• methylprednisolone 250mg
Female 63 year old,
0.90 to 1.70
2.60 mg/dL
(positive)
• plasmapharesis
Microscopic
mg/dL
• cyclophosphamide
Polyangitis,
eGFR
• Anti-MPO 80 U/ml
• Mesna
Pulmonary-renal
eGFR
19 ml/min
(ref. 0-9)
• hemodialysis catheter
syndrome
30 ml/min
2
Case 2:
Creatinine
Creatinine
• Remission:
• Rituximab 375 mg/m
Female 60 year old,
1.8 mg/dL
3.90 mg/dL
ESR 8 to 16 mm/hr
• methylprednisolone 250 mg
2007, C-ANCA, anti
eGFR
eGFR 11 mL/min
(ref. 0 – 20)
• prednisone taper
PR3 positive, FSGS
31 mL/min
• peritoneal dialysis
(biopsy)
PR3 Antibody
• Flare:
• kidney transplant list
PR3 antibody
>100 U/mL
ESR 103 mm/hr
2017, C-ANCA, anti
8 to 79 U/mL
(ref. 0 – 20)
PR3 positive, PICG
Prot/Crt ratio:
(biopsy)
Prot/Crt ratio:
2343 mg/g
34 to 81 mg/g
Case 3:
Creatinine
Creatinine
• Remission:
• kidney biopsy inconclusive
Female 78 year old,
1.37 mg/dL
1.81 mg/dL
ESR 14 mm/hr
• no steroids, osteoporosis
2
anti MPO positive,
eGFR 37 mL/min eGFR 27 mL/min
(ref. 0 – 20)
• Rituximab 375 mg/m
ANCA, glomerulo• Rituximab 500 mg
nephritis
anti MPO 4.9 AI
anti MPO 30 AI
• Flare:
maintenance to 24 months
(ref. <1.0)
(ref. <1.0)
ESR 111 mm/hr
• Elderly BMI ref. 25–30
(ref. 0 – 20)
Prot/Crt ratio:
Prot/Crt ratio:
263 mg/g
2329 mg/g
• Weight loss BMI
2
18.67 to 16.36 kg/m
Abbreviations:
ref. (reference), eGFR (estimated glomerular Filtration Rate), ESR (erythrocyte sedimentation rate), C-ANCA (cytoplasmic
anti-neutrophilic cytoplasmic antibodies), P-ANCA (peri-nuclear anti-neutrophilic cytoplasmic antibodies), MPO
(Myeloperoxidase), PR3 (Proteinase-3), PICG (Pauci immune crescentic glomerulonephritis), FSGS (Focal Segmental
glomerulosclerosis), Crt (Creatinine), Prot (Protein), Prot/Crt ratio ref. < 160

1. Tomasson meta-analysis (2012): 15 primary studies on the predictability of ANCA on relapse of disease, 9 with a total of 503
patients with a rise in ANCA and 9 with a total of 430 patients with persistently positive ANCA. Figures show analysis for Rise:
(Left) Receiver operator curve for a rise in ANCA as predictor of relapse. Estimated sensitivity of 0.56 (95% CI 0.33, 0.79) and
specificity of 0.82 (95% CI 0.75, 0.90). (Right) Positive likelihood ratio (LR+) of 2.84 (95% CI 1.65, 4.90) of a future relapse.

Serial ANCA measurements subject of controversy (Fussner 2016):
 The utility of ANCA testing has been widely accepted, but the clinical utility of ANCA as
a biomarker of disease activity and predictor of relapses has remained a controversy:
 Published data on serial ANCA testing is heterogeneous with multiple variables possibly
affecting the interpretation:
 Types of ANCA, the assays used, time intervals between measurements, definitions
of rises in ANCA titres, inclusion of subgroups of patients with different disease
manifestations and treatment chosen to induce or maintain remission.
Figure adapted from Kemna (2015)
Subgroup analysis (Kemna 2015):
Entire cohort, (hazard ratio HR 5.84; 95%
CI, 3.44 to 9.92; P<0.001)
Rise is strongly related to a relapse in
patients with renal involvement (HR, 11.09;
95% CI, 5.01 to 24.55; P<0.001)
Rise is only weakly associated with a
relapse in patients with non-renal disease
(HR, 2.79; 95% CI, 1.30 to 5.98; P=0.01).
The area up to a hazard ratio of 1 marks
the border of significance.

Conclusion

Figure adapted from Kemna (2015)

 Although measuring ANCA to predict disease activity remains controversial, this
case series demonstrates association between ANCA titers and severity of renal
disease. ANCA titers may provide prognostic value that can be useful when
discussing therapy options with the renal patient

Case 2 involves a 60 year old female with CKD stage 3 and
focal segmental glomerulosclerosis in remission who relapsed
and developed pauci-immune crescentic glomerulo-nephritis.
In case 2, anti-PR3 titer was elevated (>100 U/mL) and
associated with a 20-fold increase in the Protein/Creatinine
ratio of 2343 mg/g. She eventually required peritoneal dialysis.
Case 3 involves a 78 year old female with CKD stage 3 and
anti-MPO vasculitis in remission but developed AKI with a 6
fold increase in anti-MPO titer and 10 fold increase in
proteinuria. She was managed conservatively with rituximab.

Literature Review (Selected cases)

 Understanding the pathophysiology of disease activity and remission to help define
better biomarkers to positively affect adverse events and patient outcomes.
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